RESUMO
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder. The available therapy is mainly Acetyl cholinesterase (AChE) inhibitors and N-methyl-D-aspartate (NMDA) antagonist, which are single-target AD drugs. They are limited symptomatic treatment and their efficacy remains unsatisfactory. Due to the complexity and multifactorial etiology of AD, the multi-target-directed ligand approach is a hopeful way of searching new anti-AD drugs. Here we review the advancement of multitarget AD drugs in recent years: single compound with more than one target, multicomponent drug and drug combination.
RESUMO
Druggability is crucial in pharmaceutical drug development as the source of drug research. Druggability research will face greater challenges because Chinese materia medica (CMM) is the multicomponent drug. In this paper, ideas and methods of study on CMM druggability were mainly proposed in combination with the chemical material basis of muticomponents of CMM.
RESUMO
The core of multicomponent drug metabolism is the mutual influence of the transporters and drug metabolic enzymes interaction of more ingredients, with the simultaneous determination for multiple components as the principle, and with many components changes on the environmental impact as the emphasis. Its theoretical content composes by sequential metabolism, concurrent metabolism, and multiple metabolism. On the principles of multicomponent simultaneous determination, metabolic continuous time records, metabolic continuous space records, and the combination of qualitative and quantitative research, the multicomponent drug metabolism is researched by the experimental methods of in vivo, in situ, and in vitro. In visual mode of the comparative analysis with the quantitative data evaluation, multicomponent drug metabolism can be thought of emerging research direction with solid academic foundation and advanced technical means.